Circular Genomics: Circular Genomics Joins Lilly Gateway Labs in San Diego to Develop Circular RNA Platform for the Diagnosis and Prognosis of Alzheimer's Disease

Circular Genomics announced it is moving the company's headquarters to Lilly Gateway Labs in San Diego, California, which is operated in partnership with Alexandria Real Estate Equities Inc., to advance the development of Alzheimer's disease (AD) biomarkers aimed at improving the identification and monitoring of the disease and its risk of progression. Circular Genomics was selected to join the community at Gateway Labs, a best-in-class innovation hub that connects pioneering biotechs to Eli Lilly and Company's expertise, based on its cutting-edge circRNA platform technologies and promising diagnostic programs for neurological disorders. In September 2024, Circular Genomics launched the early access program for MindLight, the first circRNA biomarker-based blood test designed to predict the likelihood of whether a patient with major depressive disorder (MDD) will respond, or not, to selective serotonin reuptake inhibitor (SSRI) antidepressant treatment. This proprietary test is a best-in-class prognostic tool developed on Circular Genomics' circRNA platform that has the potential to provide critical predictions for a wide range of diseases. Circular Genomics' pipeline includes a number of novel diagnostic and prognostic circRNA assays in development, one of which has been demonstrated to effectively diagnose patients at high risk of AD progression and stratify their risk with very high accuracy. The potential clinical applications of the company's innovative biomarker technology range from patient stratification and candidate selection for clinical trials of disease-modifying treatments to monitoring of disease progression and therapeutic efficacy. Circular Genomics' move to Gateway Labs at the premier One Alexandria Square Megacampus aims to advance the use of circRNA biomarkers for the development of highly specialized and accurate AD diagnostic and prognostic blood tests. As a member of Gateway Labs in San Diego, Circular Genomics will have access to Lilly's scientific and operational expertise, a state-of-the-art wet lab facility, resources, networking, and an individualized plan tailored to the success of the MindLight program. Circular Genomics announced it is moving the company's headquarters to Lilly Gateway Labs in San Diego, California, which is operated in partnership with Alexandria Real Estate Equities Inc., to advance the development of Alzheimer's disease (AD) biomarkers aimed at improving the identification and monitoring of the disease and its risk of progression. Circular Genomics was selected to join the community at Gateway Labs, a best-in-class innovation hub that connects pioneering biotechs to Eli Lilly and Company's expertise, based on its cutting-edge circRNA platform technologies and promising diagnostic programs for neurological disorders. In September 2024, Circular Genomics launched the early access program for MindLight, the first circRNA biomarker-based blood test designed to predict the likelihood of whether a patient with major depressive disorder (MDD) will respond, or not, to selective serotonin reuptake inhibitor (SSRI) antidepressant treatment. This proprietary test is a best-in-class prognostic tool developed on Circular Genomics' circRNA platform that has the potential to provide critical predictions for a wide range of diseases. Circular Genomics' pipeline includes a number of novel diagnostic and prognostic circRNA assays in development, one of which has been demonstrated to effectively diagnose patients at high risk of AD progression and stratify their risk with very high accuracy. The potential clinical applications of the company's innovative biomarker technology range from patient stratification and candidate selection for clinical trials of disease-modifying treatments to monitoring of disease progression and therapeutic efficacy. Circular Genomics' move to Gateway Labs at the premier One Alexandria Square Megacampus aims to advance the use of circRNA biomarkers for the development of highly specialized and accurate AD diagnostic and prognostic blood tests. As a member of Gateway Labs in San Diego, Circular Genomics will have access to Lilly's scientific and operational expertise, a state-of-the-art wet lab facility, resources, networking, and an individualized plan tailored to the success of the MindLight program.